ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Ponatinib is an inhibitor of the tyrosine kinase BCR-ABL in chronic myeloid leukemia (CML), and its clinical trial has been approved by FDA for the treatment of the disease.